156P The impact of the COVID-19 pandemic on the treatment patterns of patients with stage III unresectable non-small cell lung cancer

• DOI: 10.1016/j.esmoop.2024.102911
• Publication Date: 2024-03-25T08:50:17Z
• Authors: P. Borghetti; K. Hsieh; B. Al-Khalidi; S. Kumar Adepu; D. Sanchez-Hernandez; L. Cai; P. Chander; Y. Qiao; N. Frost
• Keywords: Pandemic; 2019-20 coronavirus outbreak

The aim of this study was to understand the impact COVID-19 pandemic on treatment patterns for patients with stage III unresectable non-small cell lung cancer (uNSCLC). This a retrospective chart review uNSCLC diagnosed between 1 October 2017 and 31 May 2021 in France, Germany, Italy, Spain, Canada, USA. Of 351 enrolled (median age 70 years [range 44-91]; 63.5% male), 88 263 were treated prior (Cohort 1) during 2) pandemic, respectively. majority Cohort (89.8%) 2 (82.5%) received platinum-based chemoradiotherapy (CRT). Among receiving CRT, proportion who sequential CRT (sCRT) higher compared (20.3% vs 12.7%). Median durations completed concurrent sCRT 64.0 145.5 days, respectively, all similar cohorts. A consolidation durvalumab (67.3% 40.5%). Compared 1, had lower median time initiation (41.0 51.5 days since end) longer duration (336.0 147.5 days). patients, experienced dose/schedule modifications (28.1% 14.8%). experiencing any adverse events (AEs) interest (67.0%) (67.3%). AEs collected, proportions reported pneumonitis (7.8% 14.9%) interstitial disease (0% 3.2%). In study, continued receive SOC 2), durvalumab, shorter initiation, 1). Higher potentially help mitigate toxicities alleviate healthcare system burden. maintained indicating strong attention patient care increased awareness PACIFIC regimen.